Publications by authors named "Levent Mutlu"

Claim this Profile
G
Galectin-3 level in idiopathic pulmonary fibrosis patients and its relationship with response to antifibrotic treatment.
Sibel Emre, Nevin Fazlıoğlu, Ersan Emre, Levent Cem Mutlu, Ahsen Yılmaz

Respir Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of tracheal diameter with respiratory function and fibrosis severity in idiopathic pulmonary fibrosis patients.
Nevin Fazlıoğlu, Hadi Sasani, Mithat Fazlıoğlu, Ezgi Pınar Çiftçi, Levent Cem Mutlu

BMC Pulm Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic and Asthma-Related Characteristics of Asthmatics Using Pressurized Metered Dose Inhalers and Dry Powder Inhalers.
Kurtuluş Aksu, Gürgün Tuğçe Vural Solak, Levent Cem Mutlu, Pınar Mutlu, Görkem Vayısoğlu Şahin

J Aerosol Med Pulm Drug Deliv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of written asthma action plan among asthma patients in Türkiye: a multicenter, cross-sectional, descriptive study.
Kurtuluş Aksu, Gürgün Tuğçe Vural Solak, Pınar Mutlu, Levent Cem Mutlu, Görkem Vayişoğlu Şahin

Turk J Med Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.
Levent Mutlu, Blair McNamara, Stefania Bellone, Diego D Manavella, Cem Demirkiran

Clin Exp Metastasis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
Blair McNamara, Michelle Greenman, Stefania Bellone, Luca A Santin, Cem Demirkiran, Levent Mutlu

Gynecol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet needs in cervical cancer - can biological therapies plug the gap?
Michelle Greenman, Yifan Emily Chang, Blair McNamara, Levent Mutlu, Alessandro D Santin

Expert Opin Biol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara, Tobias Max Philipp Hartwich, Levent Mutlu

Gynecol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Mean Platelet Volume a Predictive Marker for the Development of Thrombosis in Patients with COVID-19 Infection?
Ilknur Erdem, Enes Ardic, Ilker Yildirim, Caglar Kavak, Levent Cem Mutlu

Kurume Med J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
Sangini S Sheth, Ji Eun Oh, Stefania Bellone, Eric R Siegel, Michelle Greenman, Levent Mutlu

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entering the golden age for antibody-drug conjugates in gynecologic cancer.
Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin

Oncoscience· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Blair McNamara, Cem Demirkiran, Tobias Max Philipp Hartwich, Stefania Bellone, Diego Manavella, Levent Mutlu

Gynecol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Stefania Bellone, Kyungjo Jeong, Mari Kyllesø Halle, Camilla Krakstad, Blair McNamara, Levent Mutlu

Proc Natl Acad Sci U S A· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting cervical cancer with anti-PD-1 antibodies: what is new?
Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin

Expert Opin Biol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Levent Mutlu, Diego D Manavella, Stefania Bellone, Blair McNamara, Justin A Harold

Mol Cancer Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu, Alessandro D Santin

Molecules· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Julia H Gelissen, Naomi N Adjei, Blair McNamara, Levent Mutlu, Justin A Harold

Ann Surg Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
Blair McNamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Blair McNamara, Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu

Gynecol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Stefania Bellone, Blair McNamara, Levent Mutlu, Cem Demirkiran, Tobias Max Philipp Hartwich

Int J Mol Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Dennis Mauricio, Stefania Bellone, Levent Mutlu, Blair McNamara, Diego D Manavella

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Chanhee Han, Blair McNamara, Stefania Bellone, Justin Harold, Paola Manara, Levent Mutlu

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
Blair McNamara, Yifan Chang, Levent Mutlu, Justin Harold, Alessandro D Santin

Expert Opin Biol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Justin Harold, Stefania Bellone, Diego D Manavell, Levent Mutlu, Blair McNamara

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Diego D Manavella, Blair McNamara, Justin Harold, Stefania Bellone, Tobias Max Philipp Hartwich, Levent Mutlu

Gynecol Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis